RCT Study of Levosimendan Improving Prognosis of Cardiac Arrest
Heart Arrest
About this trial
This is an interventional treatment trial for Heart Arrest focused on measuring cardiac arrest, Levosimendan Injection, prognosis
Eligibility Criteria
Inclusion Criteria: 1: Age>18 years old 2: After active Cardiopulmonary resuscitation, patients with cardiac arrest obtain the recovery of spontaneous circulation (ROSC), which is defined as having palpable arterial pulse lasting for more than 20 minutes 3: Patients with witnessed cardiac arrest 4: ROSC lasts for less than 60 minutes 5: Low cardiac output syndrome after ROSC (LVEF<40%) 6: Still in a coma after ROSC, Glasgow score<8 points 7: Complete enrollment within 180 minutes after ROSC Exclusion Criteria: 1: Patients receiving extracorporeal Cardiopulmonary resuscitation 2: Patients with severe neurological deficits prior to cardiac arrest 3: Patients with severe renal dysfunction (creatinine clearance rate<30ml/min) 4: Patients with confirmed or suspected pregnancy 5: Patients with Intracranial hemorrhage 6: Patients with end-stage diseases, such as advanced malignant tumors or other severe wasting diseases 7: Patients who are unwilling to participate in the study
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
Levosimendan group
Placebo group
The administration scheme of Levosimendan is continuous intravenous infusion at the rate of 0.05-0.2 μg/kg/min for 24 hours, and no load is given to reduce the risk of Hypotension.
The placebo group received continuous intravenous infusion of physiological saline at the rate of 0.05-0.2 μg/kg/min for 24 hours, while also receiving comprehensive cluster therapy with PCAS.